- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01227421
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
A Randomized, Double-Blind, Placebo Controlled Study of Nitazoxanide in Adults and Adolescents With Acute Uncomplicated Influenza
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A Randomized, Double-Blind, Placebo Controlled Study of Nitazoxanide in Adults and Adolescents with Acute Uncomplicated Influenza. The primary objectives of this study are to demonstrate the efficacy of nitazoxanide administered 300 mg two times per day for 5 days or 600 mg two times per day for 5 days in reducing the time to resolution of all clinical symptoms of influenza.
The study will also evaluate pharmacokinetics of nitazoxanide in a subset of 24 patients and the safety of the nitazoxanide regimen compared to a placebo via analysis of adverse events and laboratory safety tests.
Blood samples will be collected for all patients at baseline, day 7 and day 28, and for a subset of 24 patients aged 18-65 years (pharmacokinetics subset) on day 2. Urine samples will be collected at baseline and day 7. Nasal swabs will be collected at baseline and day 7 for all patients and on days 2, 3, 4 and 5 for a subset of patients (approximately 20% of patients).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
New York
-
Elmira, New York, United States, 14901
- Health Sciences Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
INCLUSION CRITERIA
- age 12 to 65 years
Presence of clinical signs, respiratory symptoms and constitutional symptoms compatible with influenza infection:
- fever,
- at least one of the following respiratory symptoms: cough, sore throat, nasal discharge, nasal congestion, sneezing.
- At least one of the following constitutional symptoms: headache, myalgia, seats, chills, fatigue of any severity (mild, moderate, severe)
- Confirmation of Influenza A or B infection in the local community
- Onset of illness no more than 48 hours before presentation. Time of onset of illness is defined as either the earlier of (1) the time when the temperature was first measured as elevated, or (2) the time when the patient experienced the presence of at least one respiratory symptom AND the presence of at least one constitutional symptom.
- willing and able to comply with protocol requirements and provide informed consent
EXCLUSION CRITERIA:
- severity of illness requiring or anticipated to require in-hospital care
High risk of complications from influenza as follows:
- persons with asthma or other chronic pulmonary diseases
- persons with hemodynamically significant cardiac disease
- persons who have immunosuppressive disorders or receiving immunosuppressive therapy
- persons infected with Human Immunodeficiency Virus (HIV)
- persons with sickle cell anemia or other hemoglobinopathies
- persons with diseases requiring long-term aspirin therapy
- persons with chronic renal dysfunction
- persons with liver disorders
- Persons with cancer
- Persons with chronic metabolic disease such as diabetes and inherited mitochondrial disorders
- Persons with neuromuscular disorders, seizure disorders, or cognitive dysfunction
- Residents of any age of nursing homes or long-term institutions.
- Females of child bearing age who are pregnant, breastfeeding or sexually active without birth control
- vaccination for influenza or H1N1 (Swine Flu) on or after August 1, 2010
- treatment with antiviral medication such as oseltamivir, zanamivir, amantadine, or rimantadine within 30 days of screening.
- Prior treatment with nitazoxanide within 30 days prior to screening.
- subjects with active respiratory allergies or expected to require anti-allergy medications during the study period.
- known sensitivity to nitazoxanide
- subjects unable to take oral medication
- subjects with chronic kidney or liver disease
- Presence of any other pre-existing chronic infection that is undergoing or requiring medical therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Nitazoxanide, Placebo
300 mg nitazoxanide tablet and 1 placebo tablet twice daily for 5 days
|
Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days
Other Names:
Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days
Other Names:
|
Active Comparator: Nitazoxanide, Nitazoxanide
Two 300 mg nitazoxanide tablets(600mg) twice daily for 5 days
|
Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days
Other Names:
Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days
Other Names:
|
Placebo Comparator: Placebo
2 placebo tablets twice daily for 5 days
|
Tablets, (2 tablets) twice daily with food for 5 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Resolution of All Clinical Symptoms of Influenza as Reported by the Subjects
Time Frame: Up to 28 days
|
The primary efficacy analysis for this study was to demonstrate the efficacy of Nitazoxanide (NTZ) administered as 300 mg b.i.d. for 5 days or 600 mg b.i.d. for 5 days in reducing the time to resolution of all clinical symptoms of influenza in patients with laboratory confirmed influenza infection
|
Up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Resolution of Each Individual Symptom of Influenza as Reported by the Subjects
Time Frame: at least 28 days
|
Time in hours (Median and Interquartile range)
|
at least 28 days
|
Mean Change (Standard Deviation)in 50% Tissue Culture Infective Dose (TCID50) Viral Titer From Baseline
Time Frame: 7 days
|
Change in viral titer presented as logarithm with base 10 (log10) 50% Tissue Culture Infective Dose (TCID50)
|
7 days
|
Mean Change in RT-PCR (Reverse Transcription Polymerase Chain Reaction) Viral Titer From Baseline
Time Frame: 7 days
|
Change in viral titer logarithm with base 10 (log10) Ribonucleic Acid (RNA)copies
|
7 days
|
Time to Cessation of Viral Shedding Measure by 50% Tissue Culture Infective Dose (TCID50)
Time Frame: 28 days
|
Median time in hours
|
28 days
|
Time to Return to Normal Daily Activities
Time Frame: 28 days
|
Time in hours as reported by patient
|
28 days
|
Symptom Severity Score Hours
Time Frame: 28 days
|
Sum of the symptom severity score hours from first dose to resolution of symptoms.
Patients rated each symptom's severity on a score from 0 to 3 (0=absent, 1=mild, 2=moderate, 3=severe).
Total symptom severity score hours were calculated by multiplying the sum of the severity scores by duration of symptoms.
|
28 days
|
Time Loss From Work
Time Frame: 28 days
|
Time loss from work
|
28 days
|
Complications of Influenza
Time Frame: 28 days
|
Proportion of patients with a complication of influenza during the course of the study
|
28 days
|
Influenza Antibody Response Titer Change: Influenza A 2009 H1N1
Time Frame: 28 days
|
change in influenza antibody titer for Influenza A 2009 H1N1
|
28 days
|
Influenza Antibody Response: Influenza A H3N2
Time Frame: 28 days
|
Change in antibody titer for Influenza A H3N2
|
28 days
|
Influenza Antibody Response: Influenza B
Time Frame: 28 days
|
Change in antibody titer for Influenza B
|
28 days
|
Influenza Antibody Response: Seroprotection and Seroconversion for Patients With Influenza A 2009 H1N1
Time Frame: 28 days
|
Proportion of patients seroprotected or seroconverted at day 28
|
28 days
|
Influenza Antibody Response: Seroprotection and Seroconversion for Patients With Influenza A H3N2
Time Frame: 28 days
|
Proportion of patients seroprotected and seroconverted at day 28
|
28 days
|
Influenza Antibody Response: Seroprotection and Seroconversion for Influenza B
Time Frame: 28 days
|
Proportion of patients seroprotected and seroconverted at day 28
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jean-Francois Rossignol, M.D., Ph.D., Romark Laboratories L.C.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RM08-3001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on Nitazoxanide
-
Telethon Kids InstituteWithdrawn
-
Azidus BrasilFarmoquimica S.A.; Hospital Vera Cruz; Hospital Casa de Saúde - Vera Cruz - Campinas... and other collaboratorsCompleted
-
Romark Laboratories L.C.CompletedRotavirus Infection | Norovirus Infection | Adenoviridae Infection
-
Azidus BrasilFarmoquimica S.A.Recruiting
-
Maha TalaabCompleted
-
Pinnacle Clinical Research, PLLCCompletedFatty Liver | Fibrosis, Liver | Compensated Cirrhosis | Non-alcoholic SteatohepatitisUnited States
-
Romark Laboratories L.C.CompletedRhinovirus | EnterovirusUnited States, Puerto Rico
-
Materno-Perinatal Hospital of the State of MexicoLaboratorios LiomontCompletedCoronavirus InfectionMexico
-
International Centre for Diarrhoeal Disease Research...University of VirginiaCompleted
-
Sadat City UniversityRecruitingIrritable Bowel Syndrome With DiarrheaEgypt